14.09

4.14% +0.56

GH Research PLC (GHRS)

Overview News Price History Option Chain Discussions Forecast

GH Research PLC stock is currently priced at $14.09, with a 24-hour trading volume of 53,752. It has seen a +4.14% increased in the last 24 hours and a +28.56% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.44 pivot point. If it approaches the $14.35 resistance level, significant changes may occur.

Previous Close:

$13.53

Open:

$13.69

24h Volume:

53,752

Market Cap:

$733.08M

Revenue:

Net Income/Loss:

$-35.59M

P/E Ratio:

-20.51

EPS:

-0.687

Net Cash Flow:

$-33.44M

1W Performance:

+2.85%

1M Performance:

+28.56%

6M Performance:

+125.80%

1Y Performance:

+25.80%

1D Range:

$13.69

$14.53

52W Range:

$5.05

$14.64

GH Research PLC Stock (GHRS) Company Profile

Name

GH Research PLC

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

353 1 437 8443

Address

28 Baggot Street Lower, Dublin 2, Dublin

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GHRS's Discussions on Twitter

GH Research PLC Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

GH Research PLC Stock (GHRS) Latest News

Head to Head Comparison: Acrivon Therapeutics (NASDAQ:ACRV) & GH Research (NASDAQ:GHRS) - Defense World

Defense World

GH Research PLC Stock (GHRS) Financials Data

GH Research PLC (GHRS) Net Income 2024

GHRS net income (TTM) was -$35.59 million for the quarter ending December 31, 2023, a -58.47% decrease year-over-year.

GH Research PLC (GHRS) Cash Flow 2024

GHRS recorded a free cash flow (TTM) of -$33.44 million for the quarter ending December 31, 2023, a -27.30% decrease year-over-year.

GH Research PLC (GHRS) Earnings per Share 2024

GHRS earnings per share (TTM) was -$0.68 for the quarter ending December 31, 2023, a -57.77% decline year-over-year.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.